CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer

PURPOSE: CALGB 40603 (NCT00861705), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide significantly increased the pathologic complete response (pCR) rate in stage II-III triple-negative breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Shepherd, Jonathan H., Ballman, Karla, Polley, Mei-Yin C., Campbell, Jordan D., Fan, Cheng, Selitsky, Sara, Fernandez-Martinez, Aranzazu, Parker, Joel S., Hoadley, Katherine A., Hu, Zhiyuan, Li, Yan, Soloway, Matthew G., Spears, Patricia A., Singh, Baljit, Tolaney, Sara M., Somlo, George, Port, Elisa R., Ma, Cynthia, Kuzma, Charles, Mamounas, Eleftherios, Golshan, Mehra, Bellon, Jennifer R., Collyar, Deborah, Hahn, Olwen M., Hudis, Clifford A., Winer, Eric P., Partridge, Ann, Hyslop, Terry, Carey, Lisa A., Perou, Charles M., Sikov, William M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015203/
https://www.ncbi.nlm.nih.gov/pubmed/35044810
http://dx.doi.org/10.1200/JCO.21.01506

Ejemplares similares

Ejemplares similares